These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 28129131

  • 1. 6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells.
    Zhang X, Castanotto D, Nam S, Horne D, Stein C.
    Mol Ther; 2017 Jan 04; 25(1):79-91. PubMed ID: 28129131
    [Abstract] [Full Text] [Related]

  • 2. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
    Rivest P, Renaud M, Sanderson JT.
    Chem Biol Interact; 2011 Feb 01; 189(3):177-85. PubMed ID: 21111724
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.
    Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M.
    PLoS One; 2011 Feb 01; 6(9):e25341. PubMed ID: 21980429
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines.
    Schütz SV, Cronauer MV, Rinnab L.
    J Cell Biochem; 2010 Apr 15; 109(6):1192-200. PubMed ID: 20127713
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.
    Darrington RS, Campa VM, Walker MM, Bengoa-Vergniory N, Gorrono-Etxebarria I, Uysal-Onganer P, Kawano Y, Waxman J, Kypta RM.
    Int J Cancer; 2012 Sep 15; 131(6):E872-83. PubMed ID: 22539113
    [Abstract] [Full Text] [Related]

  • 9. 6-bromo-indirubin-3'-oxime (6BIO), a Glycogen synthase kinase-3β inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts.
    Sklirou AD, Gaboriaud-Kolar N, Papassideri I, Skaltsounis AL, Trougakos IP.
    Sci Rep; 2017 Sep 15; 7(1):11713. PubMed ID: 28916781
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?
    Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler KD, Cronauer MV.
    Neoplasia; 2008 Jun 15; 10(6):624-34. PubMed ID: 18516299
    [Abstract] [Full Text] [Related]

  • 11. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
    Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.
    J Cell Biochem; 2006 Oct 01; 99(2):402-10. PubMed ID: 16741972
    [Abstract] [Full Text] [Related]

  • 12. Indirubin derivative 6BIO suppresses metastasis.
    Braig S, Kressirer CA, Liebl J, Bischoff F, Zahler S, Meijer L, Vollmar AM.
    Cancer Res; 2013 Oct 01; 73(19):6004-12. PubMed ID: 23946383
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer.
    Braig S, Bischoff F, Abhari BA, Meijer L, Fulda S, Skaltsounis L, Vollmar AM.
    Biochem Pharmacol; 2014 Sep 15; 91(2):157-67. PubMed ID: 25069048
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Indirubin Derivative 6-Bromoindirubin-3'-Oxime Activates Proteostatic Modules, Reprograms Cellular Bioenergetic Pathways, and Exerts Antiaging Effects.
    Tsakiri EN, Gaboriaud-Kolar N, Iliaki KK, Tchoumtchoua J, Papanagnou ED, Chatzigeorgiou S, Tallas KD, Mikros E, Halabalaki M, Skaltsounis AL, Trougakos IP.
    Antioxid Redox Signal; 2017 Nov 10; 27(14):1027-1047. PubMed ID: 28253732
    [Abstract] [Full Text] [Related]

  • 18. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
    McCarty MF, Hejazi J, Rastmanesh R.
    Integr Cancer Ther; 2014 Sep 10; 13(5):386-95. PubMed ID: 24867960
    [Abstract] [Full Text] [Related]

  • 19. The indirubin derivative 6-bromoindirubin-3'-glycerol-oxime ether (6BIGOE) potently modulates inflammatory cytokine and prostaglandin release from human monocytes through GSK-3 interference.
    Czapka A, König S, Pergola C, Grune C, Vougogiannopoulou K, Skaltsounis AL, Fischer D, Werz O.
    Biochem Pharmacol; 2020 Oct 10; 180():114170. PubMed ID: 32710971
    [Abstract] [Full Text] [Related]

  • 20. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL.
    Oncotarget; 2015 Oct 13; 6(31):31997-2012. PubMed ID: 26378018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.